Lorenz Mayr

+++ 𝗤𝟭 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝟮𝟬𝟮𝟰 𝗮𝗻𝗱 𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝘂𝗽𝗱𝗮𝘁𝗲 +++ We started the year with good progress across our oncology pipeline and our commercialization activities. Some key events: 🔬 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆: We and our collaboration partner Duality Biologics dosed the first patient in a Phase 3 clinical trial with our #ADC candidate BNT323/DB-1303 in breast cancer patients, advancing towards BioNTech’s goal of ten or more potentially registrational trials running by the end of 2024. 🩹 𝗖𝗢𝗩𝗜𝗗-𝟭𝟵: We are focusing on preparing for variant-strain adaptation of our COVID-19 vaccine to be ready for a commercial launch ahead of the upcoming 2024/2025 vaccination season, pending approvals. 🌎 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗿𝗲𝗮𝗱𝗶𝗻𝗲𝘀𝘀: We appointed our General Manager Fatma Ocak for the U.S. in line with our commercial preparations to drive our first expected global #oncology product launch. 𝗟𝗶𝗻𝗸 𝘁𝗼 𝗣𝗥 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: https://lnkd.in/ePDQiHbH  

549

2 Kommentare

"Conclusion: About 32% of all oncology drug approvals have evidence for an improvement in Overall Survival. Higher standards are needed in drug regulation to ensure that approved drugs are delivering better patient outcomes, specifically in regards to survival." Not good: we have to invest more in the diagnostic tests that help oncologist identify those drugs that will address the patient-specific genomic variants in play. Something is wrong when we spend only 2 - 3% of our healthcare budget on the diagnostics that drive 2/3rds or more healthcare decisions. #Oncology #Healthcare #DrugRegulation #PatientOutcomes #DiagnosticTests #HealthcareDecisions #PrecisionMedicine #NGS

2

1 Kommentar

USD 90 million for next-gen multifunctional precision immunotherapies: TOP 100 Swiss Scale-up Bright Peak Therapeutics secures its Series C. Congratulations to the team - best of success onwards! https://lnkd.in/eAGeqdfj About: Bright Peak is rapidly advancing a robust portfolio of next-generation, multi-functional, cytokine-based immunotherapies for the treatment of patients with cancer and autoimmune disease. The company accomplishs this by leveraging our world-class protein engineering capabilities and our unique cell-free technology platform to chemically synthesize and conjugate novel protein therapeutics that reflect state-of-the-art insights into cytokine and immune checkpoint biology. The financing round was led by Johnson & Johnson Innovation JJDC Inc, with new investors Venrock, KB Investment, and Northleaf Capital Partners also contributing. Returning investors include founding investor Versant Ventures, along with Fidelity Management And Research Company, RA Capital Management, Qatar Investment Authority, The Invus Group, and Alexandria Venture Investments. Bright Peak Therapeutics was ranked among the TOP 100 Swiss Startups in 2022. #TOP100SSU #SwissStartups

32

Congratulations to Viola Vogel, Mamta Chabria, and Martin Behe: Tandem Therapeutics has been accepted for the prestigious Wyss Zurich accelerator, to work on unlocking the extracellular matrix, to bring drug efficacy to the next level. A great recognition for a highly promising startup project! https://lnkd.in/eDNXehCg About: Most drug development is focused on targeting cells, overlooking the extracellular matrix that surrounds the cells. Presence of excessive matrix proteins are linked to therapeutic resistance and poor patient outcomes in fibrotic tumors and organ fibrosis. The matrix offers druggable biological real-estate to targets nodes that drive disease progression. Tandem Therapeutics' goal is to precision target this barrier and bring drugs to this disease extracellular matrix thereby enhancing safety and efficacy. Using evolutionarily optimised peptides, we are decoding complex matrix-disease biology to create breakthrough solutions for patients burdened with fibrotic diseases. Tandem Therapeutics is a spin-off of ETH Zürich and has been a winner of all stages of Venture Kick. #VentureKick #SwissStartups

130

7 Kommentare

German newsletter inv3st.de put a spotlight on Vidac Pharma last month, in an article singling out the best innovators and growth chances for investors. “Vidac Pharma […] is an exciting candidate in the field of drug research. Their innovative approach in oncology can reverse the function of cancer cells,” said the publication, which appears in English as News Financial. Vidac is a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments. It is developing two drug candidates to treat a wide range of tumors, which have shown very promising results in clinical and preclinical trials. To read the stories, go to https://lnkd.in/eFh2mpty or to https://lnkd.in/eQuDHxRN for the German version. #biotech #oncology #drugdevelopment #bioscience #cancer

7

📢 Pentixapharm AG Acquires Target Discovery Business of Glycotope GmbH, effective July 1st.  This strategic acquisition of the Berlin-based biotech company marks a significant milestone in their mission to develop novel targeted radiopharmaceuticals against a broad range of malignancies. 🌟 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗔𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻: • 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼: The deal includes a portfolio of 𝗽𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 against multiple oncology targets, 𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀, cell banks, a 𝘁𝘂𝗺𝗼𝗿 𝘁𝗮𝗿𝗴𝗲𝘁 𝗱𝗮𝘁𝗮𝗯𝗮𝘀𝗲, and essential equipment.    • 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗜𝗻𝘁𝗲𝗹𝗹𝗲𝗰𝘁𝘂𝗮𝗹 𝗣𝗿𝗼𝗽𝗲𝗿𝘁𝘆: This acquisition broadens the 𝗜𝗣 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 beyond the CXCR4 receptor, 𝗱𝗼𝘂𝗯𝗹𝗶𝗻𝗴 the 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 and expanding business and clinical opportunities.    • 𝗘𝘅𝗽𝗲𝗿𝘁 𝗧𝗲𝗮𝗺: Pentixapharm welcomes an 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝘁𝗲𝗮𝗺 𝗼𝗳 𝟰𝟬 seasoned executives, R&D specialists, and administrators from Glycotope.    • 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻: Patrik Kehler, former CSO of Glycotope, will join as Pentixapharm's 𝗖𝗦𝗢, and Henner Kollenberg, former CEO of Glycotope, will become the 𝗖𝗵𝗶𝗲𝗳 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗢𝗳𝗳𝗶𝗰𝗲𝗿.    💬 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗣𝗲𝗻𝘁𝗶𝘅𝗮𝗽𝗵𝗮𝗿𝗺'𝘀 𝗟𝗲𝗮𝗱𝗲𝗿𝘀: “Glycotope’s pipeline comprises 𝘀𝗲𝘃𝗲𝗿𝗮𝗹 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀 that can be 𝘂𝘀𝗲𝗱 𝗶𝗺𝗺𝗲𝗱𝗶𝗮𝘁𝗲𝗹𝘆 for 𝗽𝗿𝗼𝗼𝗳-𝗼𝗳-𝗰𝗼𝗻𝗰𝗲𝗽𝘁 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 as next generation radiopharmaceuticals,” said Dr. Hakim Bouterfa, CEO of Pentixapharm AG. “We look forward to 𝗺𝗮𝘅𝗶𝗺𝗶𝘇𝗶𝗻𝗴 𝘁𝗵𝗲 𝘀𝘆𝗻𝗲𝗿𝗴𝘆 of Pentixapharm’s know-how and Glycotope’s target discovery for the 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 𝗼𝗳 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 in both diagnostics and therapeutic applications.” “The transaction 𝘀𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝘀 our 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 and administrative capacities, facilitating a 𝘀𝗲𝗮𝗺𝗹𝗲𝘀𝘀 𝘁𝗿𝗮𝗻𝘀𝗶𝘁𝗶𝗼𝗻 to the 𝗙𝗿𝗮𝗻𝗸𝗳𝘂𝗿𝘁 𝗦𝘁𝗼𝗰𝗸 𝗘𝘅𝗰𝗵𝗮𝗻𝗴𝗲,” noted 𝗗𝗿. 𝗔𝗻𝗱𝗿𝗲𝗮𝘀 𝗘𝗰𝗸𝗲𝗿𝘁, Chairman of the Supervisory Board of both Pentixapharm and Eckert & Ziegler SE. This acquisition positions Pentixapharm to develop 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 by leveraging Glycotope’s 𝘂𝗻𝗶𝗾𝘂𝗲 𝗚𝗹𝘆𝗰𝗼𝗧𝗮𝗿𝗴𝗲𝘁𝘀—tumor-associated 𝗰𝗮𝗿𝗯𝗼𝗵𝘆𝗱𝗿𝗮𝘁𝗲 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲𝘀 with 𝘀𝘂𝗽𝗲𝗿𝗶𝗼𝗿 𝘁𝘂𝗺𝗼𝗿-𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰𝗶𝘁𝘆. These advancements have the potential to close the treatment gap for many solid tumors, enhancing both diagnostic and therapeutic applications. 🔗 Learn More: https://lnkd.in/eCXh35Nw #NuclearMedicine #Radiopharmaceuticals #Acquisition #PrecisionMedicine  

99

Are molecular glues the key to undruggable targets?   In case you missed it, Dr Benedict CS Cross spoke with Labiotech.eu about the growing interest in the field of molecular glues and the potential for this new modality to open up immense new possibilities in degrader drug development. Read the full article here: https://rb.gy/pnzjdu   #MolecularGlues #DrugDiscovery #DrugDevelopment

23

1 Kommentar

📢 𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐓𝐞𝐜𝐡𝐧𝐢𝐪𝐮𝐞𝐬 𝐢𝐧 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 🔬💊 In this latest review from researchers at the University of Michigan, advancements in liquid-phase separations combined with ion mobility-mass spectrometry (IM-MS) are highlighted as pivotal for next-generation biopharmaceutical characterization. This technique promises enhanced insights into biotherapeutics, improving their safety and efficacy by offering detailed analysis of their structural and compositional attributes. 🎯𝐊𝐞𝐲 𝐭𝐚𝐤𝐞-𝐚𝐰𝐚𝐲𝐬: • 𝐈𝐌-𝐌𝐒 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧: Seamlessly integrates with standard liquid-phase separations, adding a rapid, additional dimension of separation based on molecular shape and charge. 📈 • 𝐄𝐧𝐡𝐚𝐧𝐜𝐞𝐝 𝐂𝐡𝐚𝐫𝐚𝐜𝐭𝐞𝐫𝐢𝐳𝐚𝐭𝐢𝐨𝐧: Improves the analysis of monoclonal antibodies, antibody-drug conjugates, host cell proteins, glycans, and nucleic acids. 🧬 • 𝐄𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬: Provides faster, more detailed information on protein conformation, post-translational modifications, and impurities. ⏱️🔍 • 𝐁𝐫𝐨𝐚𝐝𝐞𝐫 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬: Potential to expedite drug discovery, development timelines, and clinical diagnostics. 🚀🧑‍⚕️ 🔗 For those interested in the detailed findings, please refer to the full text (behind paywall 💰): https://lnkd.in/eTAUtS3B #Biopharmaceuticals #MassSpectrometry #IMMS #Proteomics #DrugDevelopment #Biotech #PharmaTech #AnalyticalChemistry Devin Makey and Brandon Ruotolo

16

Join us at Swiss Biotech Day in Basel! Johannes Holzmeister & Robin Schonenberger are looking forward to discussing our unique approaches in drug delivery and development. #directoorgandelivery #genetherapy #advancedmedicines #humandiseasemodelling #biotechnology #SwissBioTechDay

15

1 Kommentar

𝗕𝗶𝗼𝗡𝗧𝗲𝗰𝗵 𝗱𝗼𝘂𝗯𝗹𝗲𝘀 𝗱𝗼𝘄𝗻 𝗼𝗻 𝗔𝗗𝗖 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝗠𝗲𝗱𝗶𝗟𝗶𝗻𝗸 𝗶𝗻 𝗻𝗲𝘄 $𝟭.𝟴𝗕 𝗯𝗶𝗼𝗯𝘂𝗰𝗸𝘀 𝗽𝗮𝗰𝘁 As BioNTech SE’s pipeline tilts back toward oncology, the German biotech is once again tapping a young Chinese partner in a bid for the next generation of the field’s hottest modality. It’s going back to MediLink Therapeutics for antibody-drug conjugates in a new deal that begins with $25 million and promises up to $1.8 billion down the road, plus tiered royalties should any of the ADCs make it to market. For that money, BioNTech snags the exclusive option for the global license to MediLink’s so-called TMALIN ADC platform for “several novel targets,” the companies said over the weekend. https://lnkd.in/d36Z2rXc

15

CHF 150,000 for next-gen cancer diagnosis: IMAI MedTech gets selected for final stage of Venture Kick. Congrats to the team of Francesca Catto, Robert Axelrod, and Sascha Brun. https://lnkd.in/eUXMKPma About: Cancer causes millions of deaths yearly. 2D histopathology, the main method for detecting cancer in tissue, involves the analysis of thin tissue slices. However, only a small percentage is examined, leading to false-negative results. The consequences are poor decisions, suboptimal treatments, and cancer recurrence. With its novel interdisciplinary approach combining biomedicine and mechanical engineering technologies, IMAI MedTech aims to enable doctors to adopt digital and 3D histopathology, enhancing accuracy, treatment outcomes, and ultimately improving survival rates. #VentureKick #SwissStartups

214

7 Kommentare

In this episode of Evaluating Biopharma, host Ben Locwin speaks with evitria AG CEO Stefan Schmidt about #bispecificantibodies. Dr. Schmidt goes into detail about current trends regarding the discovery and development phases of bispecific antibodies, potential manufacturing issues, and concerns over intellectual property immunity influencing consistency and production. Listen here: https://lnkd.in/eWqKHfvJ   #EBPodcast #EvaluatingBiopharma 

25

3 Kommentare

Swiss Biotech's 2024 Turnaround: Breaking Revenue Records Despite Funding Hurdles While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022 slump, the latest report from the Swiss Biotech Association and EY shows the sector’s resilience. Key takeaways from the report include... 💹 Record Revenues: Despite a global funding downturn, the Swiss biotech sector showcased resilience with a revenue spike to CHF 7.3 billion in 2023, a significant leap from the previous year. 💸 Strategic Capital Increases: Investment surged over 50%, with CHF 2 billion raised in 2023, demonstrating a robust appetite for innovative Swiss biotech ventures. 🤝 Dynamic M&A Activity: The industry remained vibrant with key mergers and acquisitions, highlighting ongoing growth and expansion opportunities within the sector. Get the full picture in Amanda Saionz's latest piece at https://lnkd.in/dnJ6DkXh

4

𝗠𝗜𝗕 - 𝗠𝗲𝗻 𝗶𝗻 𝗕𝗜𝗢 𝗮𝗰𝘁𝗶𝗼𝗻 The BIO conference is in full swing, but be aware when you enter YUMAB's booth no. 4217-01: 😎 Conversations with Alexander Ehm and Oliver Hill about the company's antibody drug discovery services might be as impressive as a neuralyzer that leaves minds prone to suggestion... There is a slight chance that you'll enjoy it. 😉 #BIO, #innovation, #SanDiego, #innovation, #drugdiscovery

161

12 Kommentare

It was very inspiring to have Matthias Steger PhD, MBA, CEO of Endogena Therapeutics, Inc. speaking at our recent conference in Montreux on ¨Endogena Therapeutics – a novel drug discovery & development paradigm¨. Mats described how starting in 2016 he built a unique phenotypic drug discovery platform from scratch, focused on using AI and machine learning to find novel small molecules that restore stem cell function. Over 7 years later, Endogena now has two clinical programs in opthalmology and Mats argues that a phenotypic approach can deliver higher translational success. Agents can also offer wider applicability than therapies targeting specific genetic deficits. Mats faced a lot of scepticism and had to address every proof point sequentially. Initially peopole did not believe that retinal stem cells were present, then that they could be activated, and then that they would migrate to where they were needed. Careful diligent experiments dismantled each of the objections in turn, gradually unlocking further funding and partnering interest. All of this has resulted in groundbreaking publications. It was very moving to hear how Mats was motivated on his journey by a friend facing blindness from retinitis pigmentosa. We wish Mats every success in this amazing journey. https://endogena.com/ Please look out for the ¨save the date¨ announcement for our 2025 conference! #swisshlg #biopharma #dealmaking #innovation #networking #endogena

42

5 Kommentare

Celebrating a USD 1.25 billion deal in Swiss biotech: TOP 100 Swiss Scale-up Numab Therapeutics AG' spin-off Yellow Jersey Therapeutics seals an impressive exit to Johnson & Johnson. Applause for the team of David Urech, their partners and investors! https://lnkd.in/dt9ZvDfn Numab Therapeutics, based in Horgen (ZH), develops multi-specific antibody-based immunotherapies for inflammation and cancer. Johnson & Johnson will acquire global rights to Numab's lead molecule NM26, a Phase 2-ready bispecific antibody targeting two pathways in atopic dermatitis (AD), for USD 1.25 billion. Yellow Jersey Therapeutics, a subsidiary of Numab, holds the rights to NM26, which targets IL-4Rα and IL-31 for AD treatment and will enter Phase 2 trials. The transaction is expected to close in the second half of 2024. Numab Therapeutics was ranked among the TOP 100 Swiss Startups in 2013, 2014, and 2021. #TOP100SSU #SwissStartups

125

2 Kommentare

𝗤𝗨𝗔𝗡𝗧𝗥𝗢 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗿𝗲𝗮𝗰𝗵𝗲𝘀 𝗮 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗕𝗼𝗲𝗵𝗿𝗶𝗻𝗴𝗲𝗿 𝗜𝗻𝗴𝗲𝗹𝗵𝗲𝗶𝗺 𝘁𝗼 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝗳𝗶𝗿𝘀𝘁-𝗶𝗻-𝗰𝗹𝗮𝘀𝘀 #𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀: QUANTRO Therapeutics GmbH, a Spin-out from the research institutes IMBA and IMP in Vienna, announced that the company has reached a key milestone in its joint R&D program with Boehringer Ingelheim. In successfully applying QUANTRO’s proprietary QUANTROseq® Transcriptional Fingerprint technology, all pre-set goals for technical proof-of-concept, cross-validation of HTS screening technology and identification of high-quality hits for a previously undruggable transcription factor were fully accomplished. For many cancer patients there are no or only limited treatment options, which is why cancer remains to be a leading cause of death worldwide, accounting for nearly one in six deaths. Transcription factors have emerged as a promising class of therapeutic targets to address currently undruggable cancers. Transcription factors are central regulators of gene expression that are commonly dysregulated in cancer and have remained largely unamenable to pharmacological intervention. The joint R&D program, which was initiated in 2022, aims at changing the implied status quo via development of transformational, first-in-class cancer treatments. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/ehQ6Nvsb Michael Bauer, Ph.D., Norbert Kraut

2

👀 Looking for innovative treatment for #HPV-associated cancers? 🥇 RDP Pharma AG has identified a first-in-class, orally available, small molecule-based new chemical entity, monovalent protein degrader which induces the proteolysis of the human papillomavirus (HPV)-associated E7 oncoprotein. 💊 Single-agent efficacy of the asset has been demonstrated in an HPV-dependent cervical cancer xenograft model. It revealed clear single-agent degradation and consequent inhibition of E7 activity. Additionally, and highly promising, no toxicity has been observed in mice. 🚀 We are excited to have RDP Pharma AG listed their innovative drug candidate on Bioneex. Curious to learn more about the innovative drug candidate? Join Bioneex to further explore partnership, in-licensing, and investment opportunities: https://bioneex.com. #HPV #cancers #E7 #oncoprotein #pharma #biotechnology #biopharma #healthcare #clinicaltrials #innovation #firstinclass #smallmolecule #NCE #newchemicalentity #Bioneex #RDPPharma

3

Julia Shanu-Wilson and Frank Scheffler are looking forward to the DMDG 5th European Biotransformation Workshop being held this Thursday 14th March at Novartis in Basel, Switzerland. There's a great line-up of topics: ·        Discussions on active metabolites and impact on drug development ·        New ways to synthesize metabolites ·        In vivo metabolite identification of oligonucleotides ·        Recommendations from recent IQ working groups on the development of targeted covalent inhibitors and best practices to conduct the Mixed Matrix Method for MIST coverage of metabolites https://lnkd.in/e6BSXfKe

20